Hereditary angioedema: how to approach it at the emergency department?
暂无分享,去创建一个
L. Arruda | E. Mansour | P. Giavina-Bianchi | M. V. Aun | F. Serpa | H. C. Chong Neto | R. Campos | A. Grumach | A. Motta | E. Toledo | S. Valle
[1] R. Senter,et al. Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy , 2019, Drug design, development and therapy.
[2] I. Braenne,et al. Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N‐terminal cleavage site of bradykinin , 2019, Allergy.
[3] A. Grumach,et al. Assessment on hereditary angioedema burden of illness in Brazil: A patient perspective. , 2019, Allergy and asthma proceedings.
[4] M. Cugno,et al. Angioedema and emergency medicine: From pathophysiology to diagnosis and treatment. , 2019, European journal of internal medicine.
[5] M. Vlková,et al. Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy , 2018, Journal of Clinical Immunology.
[6] T. Zuberbier,et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria , 2018, Allergy.
[7] A. Maetzel,et al. Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies , 2018, Orphanet Journal of Rare Diseases.
[8] I. Braenne,et al. Hereditary angioedema with a mutation in the plasminogen gene , 2018, Allergy.
[9] M. Margaglione,et al. Mutation of the angiopoietin‐1 gene (ANGPT1) associates with a new type of hereditary angioedema , 2017, The Journal of allergy and clinical immunology.
[10] C. Buchwald,et al. Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction? , 2017, Current diabetes reviews.
[11] W. Aberer,et al. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. , 2017, The journal of allergy and clinical immunology. In practice.
[12] M. C. Lopez-serrano,et al. An ABC of the Warning Signs of Hereditary Angioedema , 2017, International Archives of Allergy and Immunology.
[13] A. Kaplan,et al. Pathogenesis of Hereditary Angioedema: The Role of the Bradykinin-Forming Cascade. , 2017, Immunology and allergy clinics of North America.
[14] Kenneth H. Lai,et al. Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record. , 2017, The journal of allergy and clinical immunology. In practice.
[15] J. Bernstein,et al. Angioedema in the emergency department: a practical guide to differential diagnosis and management , 2017, International Journal of Emergency Medicine.
[16] Dirceu Solé,et al. Diretrizes brasileiras para o diagnóstico e tratamento do angioedema hereditário - 2017 , 2017 .
[17] J. Bernstein,et al. Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency , 2016, Pediatrics.
[18] T. Machnig,et al. Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor Deficiency. , 2016, The Journal of emergency medicine.
[19] K. Bork,et al. Hereditary angioedema with normal C1‐INH with versus without specific F12 gene mutations , 2015, Allergy.
[20] I. Jáuregui,et al. Management of angioedema without urticaria in the emergency department , 2014, Annals of medicine.
[21] I. Ball,et al. Prognostic factors in outcome of angioedema in the emergency department. , 2014, Allergy and Asthma Proceedings.
[22] K. Bork. Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema. , 2014, Immunotherapy.
[23] M. Triggiani,et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group , 2014, Allergy.
[24] A. Sheffer,et al. Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency , 2014, BMC Gastroenterology.
[25] C. Camargo,et al. A consensus parameter for the evaluation and management of angioedema in the emergency department. , 2014, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[26] W. Aberer,et al. Open‐label, multicenter study of self‐administered icatibant for attacks of hereditary angioedema , 2014, Allergy.
[27] J. Bernstein,et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[28] M. Triggiani,et al. Guidance for diagnosis and treatment of acute angioedema in the emergency department: consensus statement by a panel of Italian experts , 2014, Internal and Emergency Medicine.
[29] M. Scarpellini,et al. Drug-induced angioedema: experience of Italian emergency departments , 2013, Internal and Emergency Medicine.
[30] Henry E. Wang,et al. National estimates of emergency department visits for angioedema and allergic reactions in the United States. , 2013, Allergy and asthma proceedings.
[31] W. Aberer,et al. Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment , 2013, PloS one.
[32] C. Bethune,et al. Acute angioedema: recognition and management in the emergency department , 2013, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.
[33] R. Lockey,et al. WAO Guideline for the Management of Hereditary Angioedema , 2012, The World Allergy Organization journal.
[34] K. Bork,et al. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. , 2012, The Journal of allergy and clinical immunology.
[35] Jay L. Martello,et al. Ecallantide for treatment of acute attacks of hereditary angioedema. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[36] Tom Bowen,et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. , 2012, The Journal of allergy and clinical immunology.
[37] T. Machnig,et al. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks – final results of the I.M.P.A.C.T.2 study , 2011, Allergy.
[38] C. Town,et al. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[39] William H. Yang,et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.